The potential use of combining epigenetic therapy and immunotherapy is currently being investigated in a phase II study of 5-azacitidine and entinostat in patients with metastatic HER2- breast cancer or TNBC (NCT02453620) [249]. The gene discussed is ERBB2; the disease is breast carcinoma.